ST. JOSEPH, Mich., Oct. 30 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that Elan Pharmaceuticals, Inc. licensed its flagship data analysis suite MetaCore(TM). The platform will be available to all scientists in research. MetaCore is designed for functional analysis of biological and chemistry data. Elan will use MetaCore in their neurology and autoimmune programs.
"We are very pleased that Elan chose GeneGo and we have had good interactions so far," said Julie Bryant, GeneGo's VP of Business development. "MetaCore has substantial knowledge content coverage in the areas of CNS and autoimmune diseases, which the Elan scientists can leverage in their innovative research."
GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.5(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.5(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at http://www.genego.com.
MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM), MetaMiner(TM) and 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.
CONTACT: Julie Bryant, VP Business Development and Marketing of GeneGo,
Inc., +1-858-756-7996, firstname.lastname@example.org
Web site: http://www.genego.com/